Adjuvant olaparib for patients with germline BRCA-mutated, high-risk, HER2-negative early breast cancer: real-world data from a French early access program.
Frenel JS, Gonçalves A, Quintin J, Johnson A, Alexandru C, Olympios N, Rigal O, Bonnard C, Lahouegue A, Lazreg F, Suau D, Debbache A, de Nonneville A
The online reader was unable to display this document directly. This may occur if the repository host is temporarily unreachable, or if security restrictions (CORS) prevent embedded viewing.